4D Molecular Therapeutics Statistics Share Statistics 4D Molecular Therapeutics has 46.7M
shares outstanding. The number of shares has increased by -10.86%
in one year.
Shares Outstanding 46.7M Shares Change (YoY) -10.86% Shares Change (QoQ) 0.05% Owned by Institutions (%) 77.3% Shares Floating 42.62M Failed to Deliver (FTD) Shares 4 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 4.14M, so 8.87% of the outstanding
shares have been sold short.
Short Interest 4.14M Short % of Shares Out 8.87% Short % of Float 9.23% Short Ratio (days to cover) 1.03
Valuation Ratios The PE ratio is -1.87 and the forward
PE ratio is -1.83.
4D Molecular Therapeutics's PEG ratio is
-0.12.
PE Ratio -1.87 Forward PE -1.83 PS Ratio 8120.72 Forward PS 109.3 PB Ratio 0.59 P/FCF Ratio -2.17 PEG Ratio -0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 14.92,
with a Debt / Equity ratio of 0.05.
Current Ratio 14.92 Quick Ratio 14.92 Debt / Equity 0.05 Debt / EBITDA -0.13 Debt / FCF -0.18 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $163 Profits Per Employee $-708.67K Employee Count 227 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -55.85% in the
last 52 weeks. The beta is 2.85, so 4D Molecular Therapeutics's
price volatility has been higher than the market average.
Beta 2.85 52-Week Price Change -55.85% 50-Day Moving Average 5.55 200-Day Moving Average 4.84 Relative Strength Index (RSI) 59.46 Average Volume (20 Days) 1,120,840
Income Statement In the last 12 months, 4D Molecular Therapeutics had revenue of 37K
and earned -160.87M
in profits. Earnings per share was -2.98.
Revenue 37K Gross Profit 37K Operating Income -187.84M Net Income -160.87M EBITDA -187.84M EBIT -187.84M Earnings Per Share (EPS) -2.98
Full Income Statement Balance Sheet The company has 149.34M in cash and 24.61M in
debt, giving a net cash position of 124.73M.
Cash & Cash Equivalents 149.34M Total Debt 24.61M Net Cash 124.73M Retained Earnings -576.2M Total Assets 473.64M Working Capital 268.61M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -134.59M
and capital expenditures -3.79M, giving a free cash flow of -138.37M.
Operating Cash Flow -134.59M Capital Expenditures -3.79M Free Cash Flow -138.37M FCF Per Share -2.57
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.
Gross Margin 100% Operating Margin -507678.38% Pretax Margin -434778.38% Profit Margin -434778.38% EBITDA Margin -507678.38% EBIT Margin -507678.38% FCF Margin -373975.68%
